Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review - Son Haberler